Group 1 - The core business of Shandong Boyuan Pharmaceutical Chemical Co., Ltd. includes the research, production, and sales of fine chemicals, with a focus on organic iodides (74.56% of revenue), specialty functional chemicals (12.79%), trading (9.94%), and others (2.72%) [2] - As of December 10, 2025, the company reported a revenue of 1.073 billion yuan, representing a year-on-year growth of 6.60%, while the net profit attributable to shareholders decreased by 22.53% to 132 million yuan [2] - The company has distributed a total of 88.408 million yuan in dividends since its A-share listing [3] Group 2 - On December 19, 2025, Boyuan shares increased by 0.53%, with a trading volume of 93.8648 million yuan, and a net financing purchase of 448,700 yuan [1] - The total margin trading balance for Boyuan shares reached 142 million yuan, accounting for 3.68% of the circulating market value, which is above the 70th percentile of the past year [1] - As of December 19, 2025, there were no shares sold or repaid in the securities lending market, indicating a high level of demand for borrowing [1]
博苑股份12月19日获融资买入769.10万元，融资余额1.42亿元